SCHEMBL5897176

SCHEMBL5897176

Nc1cc(NC(=O)c2ccnc(N3CCOCC3)c2)ccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 2/20 0.62
MAPK14 Q16539 6/20 0.60
PPARG P37231 1/20 0.56
PIK3CA P42336 1/20 0.55
BRAF P15056 7/20 0.54
RAF1 P04049 6/20 0.54
HSPB1 P04792 1/20 0.52
MAPK12 P53778 1/20 0.52
MAPK11 Q15759 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 1/20 0.51
IKBKB O14920 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896834 0.88 MAPK14 (0.66) MAPK13MAPK14PPARGPIK3CABRAF
SCHEMBL4827539 0.87 MAPK14 (0.66) MAPK13MAPK14BRAFRAF1HSPB1
SCHEMBL31524076 0.87 MAPK14 (0.66) MAPK13MAPK14BRAFRAF1HSPB1
SCHEMBL6253060 0.86 MAPK13 (0.61) MAPK13MAPK14PPARGPIK3CABRAF
SCHEMBL27461654 0.85 MAPK13 (0.60) MAPK13MAPK14PIK3CABRAFRAF1
SCHEMBL5897367 0.85 MAPK14 (0.67) MAPK13MAPK14PPARGPIK3CABRAF
SCHEMBL6254089 0.84 MAPK13 (0.61) MAPK13MAPK14PPARGPIK3CABRAF
SCHEMBL5897072 0.83 MAPK14 (0.64) MAPK13MAPK14PPARGBRAFRAF1
SCHEMBL4833700 0.83 MAPK13 (0.61) MAPK13MAPK14PIK3CABRAFRAF1
SCHEMBL5897206 0.81 MAPT (0.62) MAPK13MAPK14PPARGBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 MAPK13 3605/4885MAPK14 2563/4885PPARG 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.